New Data Show RINVOQ® (upadacitinib) Demonstrated Super

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

North Chicago , Illinois , United States , Chicago , Ohio , Fiji , Viti , Roopal Thakkar , J Clin Dermatol , Exchange Commission , Program To Assess Adverse Events , Twitter , Abbvie Inc , Eczema Area , Severity Index , Worst Pruritus Numerical Rating Scale , Atopic Dermatitis , Important Safety , Medication Guide , Consumer Brief Summary , Full Prescribing Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Global Epidemiology , Ann Nutr , Nat Rev Dis , Adolescents With Uncontrolled Moderate , Severe Atopic Dermatitis , Term Efficacy , Moderate To Severe Atopic Dermatitis , Results Through Week , Label Extension Trial , Healthcare Claims Data , Evaluate Efficacy , Adult Participants With Axial Spondyloarthritis , Study Comparing Upadacitinib , Rheumatoid Arthritis Who Are , Stable Dose , Who Have , Inadequate Response , Maintenance Therapy , Subjects With Moderately , Severely Active Ulcerative , Placebo Controlled Study , Endoscopic Remission , Severely Active Crohn , Disease Who Have Inadequately Responded , Are Intolerant , Participants With Psoriatic Arthritis Who Have , Adult Patients With Moderate , Evaluate Upadacitinib , Adults With Moderate , Combination With Topical Corticosteroids , Adult Participants With Moderate , Giant Cell Arteritis , Takaysu Arteritis , Assess Adverse Events , Disease Activity , Oral Upadacitinib , Severe Systemic Lupus Erythematosus , Assess Change , Adverse Events , Adolescent Participants With Moderate , Severe Hidradenitis Suppurativa Who Have Failed , Study To Assess Adverse Events , Upadacitinib Oral Tablets , Adolescent Participants With Vitiligo , Upadacitinib Tablets ,